Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 04 August 2006
Research and development deal with
Intervet Pharma
Oxford BioMedica and Intervet Pharma R+D announced in January 2003 that they had signed a research agreement for the development of TroVax-Vet
Under the terms of this agreement BioMedica and Intervet aim to complete a license for the commercialisation of TroVax-Vet This will include an option to acquire a number of other veterinary cancer products arising from BioMedica's antigen discovery programme
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
The agreement replaces a previous agreement between Oxford BioMedica and Virbac.
TroVax-Vet is a veterinary version of Oxford BioMedica's lead human cancer product TroVax.
Both products are designed to stimulate a cancer patient's immune system to destroy tumour cells anywhere in the body.
The products are composed of an engineered vector containing a gene encoding a tumour-specific antigen.
When TroVax is injected it stimulates a potent immune response which is targeted against any cell with the antigen on its surface.
This results in a response that is directed only to the patient's tumour cells.
The human product TroVax has recently completed successful Phase I/II trials in colorectal cancer patients.
In these trials TroVax was shown to be safe and extremely efficient at inducing appropriate immune responses.
TroVax is expected to complete a Phase II study in colorectal cancer, in combination with chemotherapy, during 2003 and be ready for Phase III studies by the end of the year.
In addition the indications for TroVax will be broadened in a series of additional Phase II trials during 2003.
Commenting on the new relationship, Oxford BioMedica's chief executive, professor Alan Kingsman said: "We are delighted to be working with Intervet, one of the world's top veterinary companies.
"The commitment to rapid product development is particularly pleasing.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
